Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878367 | 0.90 | PARP14 (0.81) | PARP14 | |
| SCHEMBL31488020 | 0.90 | PARP14 (0.81) | PARP14 | |
| SCHEMBL29733506 | 0.78 | KIF11 (0.63) | PARP14 | |
| SCHEMBL208113 | 0.78 | KIF11 (0.63) | PARP14 | |
| SCHEMBL6326388 | 0.78 | ALDH1A1 (0.65) | PARP14 | |
| SCHEMBL191654 | 0.76 | KIF11 (0.61) | PARP14 | |
| SCHEMBL30521516 | 0.76 | KIF11 (0.61) | PARP14 | |
| SCHEMBL51674 | 0.76 | KIF11 (0.61) | PARP14 | |
| SCHEMBL3077145 | 0.75 | JAK2 (0.68) | PARP14 | |
| SCHEMBL30600352 | 0.75 | PARP14 (0.59) | PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2025072664-A1 | NOVEL SMALL MOLECULE INHIBITORS OF TOPBP1-BRCT7/8 THAT EXERT ANTI-MYC ACTIVITY AND SYNERGY WITH INHIBITORS OF PARP1/2 AND PARP14 | BAYLOR COLLEGE OF MEDICINE (US) | 2025-04-03 | — | — | WO | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260115285-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2026-04-30 | — | — | US | disclosed |
| CN-121800813-A | Carbazole compound embedded with boron-nitrogen unit, and synthetic method and application thereof | 天津理工大学 | 2026-04-07 | — | — | CN | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250250310-A1 | COMBINATION THERAPY WITH ADP-RIBOSE BINDING PEPTIDE AND ADP-RIBOSE FOR PREVENTION OR TREATMENT OF CANCER | PearlsInMires Co., Ltd. (KR) | 2025-08-07 | — | — | US | disclosed |
| EP-4582101-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250127907-A1 | PARP INHIBITORS | Stablix, Inc. | 2025-04-24 | — | — | US | disclosed |
| WO-2024048542-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2024-03-07 | — | — | WO | disclosed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023160708-A1 | INDOLONE-SUBSTITUTED-1,3-THIAZOLIDINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 复旦大学 | 2023-08-31 | — | — | WO | disclosed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | disclosed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | disclosed |
| CN-114634496-A | Indolone substituted-1, 3-thiazolidone derivative and preparation method and application thereof | 复旦大学 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115285-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | PARP11, PARP1, PARP14 | PARP14 3/4885 |
| US-20250250310-A1 | COMBINATION THERAPY WITH ADP-RIBOSE BINDING PEPTIDE AND ADP-RIBOSE FOR PREVENTION OR TREATMENT OF CANCER | PARP1, PARP11, PARP3 | PARP14 7/4885 |
| US-20250127907-A1 | PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP14 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.